Announcements Trials
Browse Landscape

Phase

Phase 3 5

Status

Completed 5Withdrawn 1

Sponsor Class

INDUSTRY 5OTHER 2OTHER_GOV 1NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 2

Conditions

Leiomyoma 5Uterine Hemorrhage 2

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × INDUSTRY × ulipristal acetate × Clear all
NCT01629563 2019-09-04

PEARLIV

PregLem SA

Phase 3 Completed
451 enrolled 14 charts

Leiomyoma

NCT02147158 2019-06-04

A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas

Allergan

Phase 3 Completed
432 enrolled 16 charts
Gynecologic

Leiomyoma, Uterine Hemorrhage

NCT02147197 2019-04-30

A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas

Allergan

Phase 3 Completed
157 enrolled 11 charts
Gynecologic

Leiomyoma, Uterine Hemorrhage

NCT01156857 2016-01-15

PEARLIII

PregLem SA

Phase 3 Completed
209 enrolled

Leiomyoma

NCT01252069 2016-01-13

PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study)

PregLem SA

Phase 3 Completed
132 enrolled

Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡